Join
Live feed
·
PRReleasevia Quantisnow
Eli Lilly and Company logo

FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata

ByQuantisnow·Wall Street's wire, on your screen.
LLY· Eli Lilly and Company
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LLY (Eli Lilly and Company) and more on Quantisnow.